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Effects of atrial natriuretic peptide on distal tubule function in humans.
To characterize the actions of atrial natriuretic peptide (ANP) in the
human distal nephron, we studied interactions between ANP (0.02
pg/kg . mm i.v.) and acutely administered substances acting in the
distal nephron, that is, amiloride and aldosterone, in six healthy humans
during maximal water diuresis. ANP increased NaCI excretion, frac-
tional lithium excretion (FELl) and decreased diluting segment reab-
sorption estimated from free water clearance. Amiloride increased
natriuresis, had no effect on FELL, but decreased diluting segment
reabsorption. Aldosterone had the opposite effect. When infused in
addition to amiloride, ANP still increased NaCl excretion, the changes
in sodium handling parameters being comparable to those seen after
ANP alone. Amiloride did not increase the further natriuretic response
to ANP. These findings suggest that ANP increases distal sodium
delivery, and decreases sodium reabsorption in distal segments by a
mechanism also sensitive to amiloride. ANP abolished much of the
antinatriuretic effect of aldosterone, which may also be explained by
assuming a partial overlap of the target segments of ANP and aldoste-
rone in the distal nephron. Remarkably, in neither of these experiments
was the natriuresis after ANP accompanied by a kaliuresis, for which
the explanation remains obscure.
The natriuretic mechanism of ANP probably involves an
increase in filtration rate and distal sodium delivery [1, 21. At
the same time, ANP inhibits sodium reabsorption in the collect-
ing ducts; without this effect, the increased distal delivery
would cause less natriuresis [3, 4]. In direct studies sodium
reabsorption in the rat inner medullary collecting duct (IMCD)
was shown to be inhibited [3—5]. The presence in IMCD cells of
ANP-specific receptors [6] which respond to ANP with cGMP
accumulation [7] and with inhibition of oxygen consumption [8]
is in agreement with an action of ANP on sodium transport in
this segment. Lately, ANP was also shown to stimulate cGMP
production [9] and to decrease sodium reabsorption [10] in the
rat cortical collecting duct. In addition, ANP impairs water
reabsorption in the rabbit cortical collecting duct [11].
Data on effects of ANP in the human distal nephron (defined
here as the terminal nephron starting with the late distal tubule)
are not available. Such information may be obtained by com-
bined administration of ANP and substances of which the
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actions in this segment are known. Amiloride, for instance,
decreases sodium reabsorption by inhibiting apical sodium
channels in the distal convoluted tubule, perhaps mainly in its
late portion [12], and the collecting tubules [13, 14]. Since the
natriuretic action of ANP in the collecting tubules is probably
mediated by inhibition of amiloride-sensitive sodium entry [15],
pretreatment with amiloride may eliminate any distal action of
ANP. In this setting the natriuretic effect of ANP would be
minimal if its distal action is the main cause of the natriuresis.
On the other hand, an enhanced natriuretic effect might result if
the main site of action of ANP is upstream from the distal
nephron.
Another approach is to alter aldosterone activity. The anti-
natriuretic action of aldosterone is probably localized mainly in
the late distal tubule and cortical collecting tubule [16—18].
Consequently, acute aldosterone administration will diminish
sodium delivery to the IMCD. The natriuretic effect of ANP
would be greatly curtailed if this were its main site of action. In
contrast, in view of the possible action of ANP in the cortical
collecting tubule [10], ANP may directly interfere with the
antinatriuretic effect of aldosterone. Thus, to further define the
effects of ANP in the human distal nephron in vivo we studied
in healthy humans the natriuretic response to ANP after pre-
treatment with either amiloride or aldosterone.
Methods
Studies were carried out in six healthy volunteers (3 males, 3
females), age range 21 to 28 years. Informed consent was
obtained and the study was approved by the Hospital Ethical
Committee for Studies in Humans.
The subjects took a diet containing 100 mmol Na and 100
mmol K, as outpatients, for eight days. Clearance studies were
performed on day 5 and day 8. After an interval of 14 days the
diet was restarted, and an additional clearance study was
performed on day 5.
The diets were provided by the metabolic ward. Here the
subjects returned daily for weighing and to deliver 24-hour urine
collections. Lithium carbonate (400 mg) was taken at 10p.m. on
the eve of each clearance study. After a light standardized
breakfast (containing 15 mmol Na and 15 mmol K) at 7a.m., the
subjects took the supine position. At 10 a.m. the subjects drank
a water load of 20 ml/kg, and additional water equivalent to
urine output was supplied for the remainder of the clearance
study. A constant infusion of inulin (to estimate glomerular
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filtration rate, GFR) into a lower arm vein was started, pre-
ceded by a priming dose. After at least one hour of equilibra-
tion, and when urine osmolality had reached a minimal value,
three, spontaneously-voided 20-minute urine collections were
made. Then a 90 minute i.v. ANP infusion (0.02 p.g/kg. mm)
was started, preceded by a bolus injection of 25 tg (human
ANP 99-126, Bissendorf Peptide GmbH, Hannover, FRG).
During the infusion period three additional, 30-minute urine
collections were made, and the clearance studies were generally
finished around 2 p.m. Blood samples for clearance calculations
were taken halfway through each collection period via an
intravenous canula placed on the lower arm, contralateral to the
infusion arm. Blood for plasma renin activity (PRA), aldoste-
rone and ANP was taken 10 minutes before and 75 minutes after
the start of the ANP infusion. Blood pressure was recorded
with an automatic oscillometer device (Omega 1000, Invivo
Res. Lab. Inc., Oklahoma, USA) at five-minute intervals.
Each subject underwent three clearance studies. One was a
control study, performed as outlined above. The other two were
done during administration of either amiloride or aldosterone.
These drugs were administered only on the days of the clear-
ance studies. Amiloride (MSD, Rahway New York, USA) was
taken orally in one dose (15 mg) at 8 a.m.; aldosterone (Ciba
Geigy GmbH, Wehr, Switzerland) was given i.v. as a 1 mg
bolus, followed by 0.5 mg/hour throughout the clearance study.
These three clearance studies were performed in a randomized
order.
Urine and blood samples were analyzed for osmolality (freez-
ing point depression), sodium and potassium (flame photome-
try), chloride (technicon RA-autoanalyzer, Tarrytown, New
York, USA), lithium (Perkin Elmer 3030 Atomic Absorption
Spectrophotometer, Norwalk, Connecticut, USA), and inulin.
Inulin was hydrolyzed to fructose and then determined photo-
metrically with indolacetic acid [191. PRA and plasma aldoste-
rone [20] were determined by radioimmunoassay. ANP was
extracted from 2.5 ml plasma by reversed phase chromatogra-
phy using Baker butyl-silane wide pore extraction columns
(Philipsburg, New Jersey, USA), followed by elution with
methanol/trifluoro-acetic acid 99:1 vol/vol (recovery of ANP
62%). After evaporation the extract was dissolved in RIA
buffer. Aliquots were used for determination by radioimmuno-
assay using antibody of Peninsula Laboratories (Merseyside,
UK) according to the manufacturer's instructions (coefficients
of variation inter-assay 17%, intra-assay 11%, ED50 8 fmol,
lower limit of sensitivity 0.5 fmol). Values were corrected for
percent recovery.
Calculations, statistical analysis
Mean arterial blood pressure was calculated as the sum of
one third of the systolic pressure plus two thirds of the diastolic
pressure. Clearances were calculated according to standard
formula. Free water clearance (CH,o) during maximal water
diuresis was taken as an index of sodium reabsorption in the
diluting segment, that is, distal to the point of isotonicity in the
medullary ascending limb of Henle's loop. Changes in fractional
CH2O augmented by fractional chloride clearance, written as
[(CH20 + C1)/C111], were taken as an index of changes in
fractional solute delivery to the diluting segment, and changes
in the equation [(CH20)/(CH2O + Cr1)] as an index of changes in
Table 1. Steady state data before the clearance studies
Control Amiloride Aldosterone
Body weight kg 71.6 4.4 71.4 4.4 71.7 4.3
Urine sodium 101 13 94 11 94 6
mmol/24 hr
Urine potassium 79 6 72 9 66 6
mmol/24 hr
diluting segment reabsorption. The validity of these equations
has been discussed by others [21].
Values are given as the mean standard error. PRA and
aldosterone data were evaluated after logarithmic transforma-
tion. Statistical analysis was performed using two-way analysis
of variance of a randomized block design. If the variance ratio's
obtained by this method reached statistical significance, the
differences between the means were analyzed at 5% and 1%
significance level by the Least Significance Difference test.
Results
There were no significant differences in body weight, mean
arterial pressure and 24 hour excretion of sodium and potassium
prior to the clearance studies (Table 1).
Effects of ANP
Figure 1 shows that there was a gradual rise in sodium
excretion throughout the ANP infusion in each of the three
clearance studies. The largest changes were present in the third
collection period. For subsequent presentation and evaluation
of the data (Table 2 and Fig. 2) this collection period was
compared to baseline, taken as the mean of the final two
collection periods prior to ANP infusion.
In the control study absolute and fractional sodium chloride
excretion increased to approximately twofold after ANP (Table
2). There was only a slight rise in GFR which did not reach
significance. Potassium excretion decreased (Fig. 1, Table 2).
Fractional excretion of lithium increased. No significant change
was found in maximal urine flow, free water clearance and
diluting segment delivery term, although each of these items
tended to increase. There was a rise in minimal urine osmolality
and a decrease in diluting segment reabsorption, as assessed by
the term [(CH2O)/(CH2O + C1)]. The infusion of ANP was
accompanied by an about sevenfold rise in plasma immunore-
active ANP, and a decrease in plasma renin activity and
aldosterone (Table 3). There was no consistent change in blood
pressure.
Effects of amiloride
Amiloride increased sodium excretion about threefold com-
pared to control (Fig. 2). There also was marked potassium
retention. No significant change was found in GFR, maximal
urine flow, fractional lithium excretion and the diluting segment
delivery term, but minimal urine osmolality increased and the
diluting segment reabsorption term decreased compared to
control. When infused in this setting ANP had an additional
natriuretic effect, and sodium excretion rate was higher than in
the corresponding phase of the control study. The absolute
increment in sodium excretion in the third 30-minute period of
ANP was 106 54 mol/mjn, somewhat less than observed in
Table 2. Clearance data
Fig. 1. Changes from baseline (0 mm) in
urine sodium excretion ( UN,V) and
potassium excretion ( U,V) during 90
minutes of ANP infusion in control conditions
(—0—), and after pretreatment with amiloride
(—A—) or aldosterone (——). The rise in
sodium excretion was always significant at 90
minutes of infusion (P < 0.01, not indicated in
the figure); urine potassium excretion fell
significantly in the control study (P < 0.05)
but not in the other two studies.
Control Amiloride Aldosterone
Baseline ANP Baseline ANPBaseline ANP
mI/mm
Urine sodium molImin
Urine potassium jmol/min
Urine chloride xmol/min
Urine osmolality mOsmol/kg
Urine flow mI/mm
119 9
124 27
133 13
116 25
61 3
13.3 1.4
127 5
281 83"
81 8"
200 73
67 5"
14.5 2.1
115 10
361 48''
54 8"
185 24C
79
14.3 1.7
124 10
467 83b,d
47 8C
293 55b,d79 d
16.4 2.0
113 8
24 7"
118 14
48 lOC
60 5
11.5 1.3
132 ioa
215 96"
107 l5C
202 88"
62 5"
16.8 3.1"
FENa %
FELl %
CH2o/C,flUIIfl %(CH20 + C,)/(C,,10) %
(CH20)I(CH2O + Ce,) %
0.77 0.16
25.7 2.0
8.7 0.7
9.7 0.8
90.2 1.4
1.60 0.44"
28.1 2.4a
9.1 0.9
10.8 1.3
85.6 29b
2.34 0.23
26.2 1.7
8.9 0.6
10.5 0.8
84.5 1.4"
2.70 0.38a
29.1 l.4
9.1 0.7
11.4 1.0
80.6 l.9
0.15 0.04
26.6 2.3
8.0 0.8
8.5 0.8
95.2 0.6"
1.09 0.45a
31.7 25b
9.6 12b
11.0 17b
89.2 3.1"
Data before ("baseline") and during the 3rd half hour of ANP infusion ("ANP") in control conditions, and after pretreatment with amiloride
or aldosterone. Abbreviations are: C, clearance; FE, fractional excretion; ANP, atrial natriuretic peptide.
Significant differences between baseline period and ANP infusion are denoted by a P < 0.05, and b p < 0.01. Significant differences between
control values and corresponding values in either of the other two studies are indicated by P < 0.05, and d p < 0.01.
the control study (157 59 /.Lmollmin), but this difference was
not significant. Again, the natriuresis was accompanied by an
increase in the fractional lithium excretion and a fall in the term
[(CH20)/(CH20 + Cc,)], although there was no further change in
minimal urine osmolality. Potassium excretion was unaltered
(—7.4 molImin, NS), in contrast with the control study (—52.3
mol/min, P < 0.05). The changes in hormonal parameters
were comparable to the changes observed in the control study.
Effects of aldosterone
Aldosterone increased plasma aldosterone concentration
substantially (Table 3). Sodium excretion decreased markedly,
whereas potassium excretion did not change. While there was
no significant influence of aldosterone on fractinal lithium
excretion, maximal urine flow and free water clearance tended
to be lower than in control conditions. The diluting segment
reabsorption term was now elevated. In this situation too, ANP
infusion increased sodium excretion, the absolute rise (191 90
xmo1/min in the third half hour of ANP) again being not
significantly different from the increase seen in the control
study (Fig. 1). Different from the other two studies, the rise in
GFR and urine flow during ANP infusion now reached signifi-
cance. There was a marked rise in fractional lithium excretion
as well. The diluting segment reabsorption term again de-
creased, but remained relatively high as compared to the
control study. The changes in plasma renin activity and ANP
were similar compared to the control study. There was a
tendency for plasma potassium to be lower during aldosterone
infusion. Again, potassium excretion did not change (—12
prnol/min, NS).
Discussion
The main finding of the present study in humans is that ANP
retained its natriuretic effect after a high dosage of aldosterone,
even though the latter reduced pre-ANP sodium excretion
markedly. The absolute increase in sodium excretion after ANP
was also not influenced by pretreatment with amiloride, al-
though this drug had increased pre-ANP sodium excretion.
The effects of ANP infusion on renal function were compa-
rable to those seen earlier [22, 23]. In short, the data are
compatible with increased filtered load and decreased fractional
reabsorption of sodium. The fractional excretion of lithium, a
rough index of end-proximal sodium delivery [24], increased,
while the term [(CH20)/(CH,o + Ce,)], representing diluting
segment reabsorption [21], decreased. The term [(CH,o +
and maximal urine flow tended to increase, a!-
though these changes were not as marked as seen in earlier
studies using similar dosage of ANP [22, 23]. Despite method-
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Table 3. Effects of ANP on humorat factors, plasma potassium and blood pressure
Control Amiloride Aldosterone
Baseline ANP Baseline ANPBaseline ANP
PRAfmoIAJ/J s
Aldosterone pmollliter
ANPpmol/liter
Plasma K mmol/liter
MAPmmHg
250 63
311 90
23 5
3.83 0.11
89±2
167 45b
172 28"
168 26"
3.70 0.15
90±2
198 66 159 40C
265 74 130 38
20 4 203 39"
3.93 0.16 3.87 0.08
87±2 84±2
282 83
28000 5146"
21 3.0
3.48 0.11
88±3
217 74
28000 4137"
174 31"
3.47 0.10
87±3
Data before ("baseline") and during the 3rd half hour of ANP infusion ("ANP") in control conditions, and after pretreatment with amiloride
or aldosterone. Abbreviations are: PRA, plasma renin activity; ANP, atrial natriuretic peptide; MAP, mean arterial pressure.
Significant differences between baseline period and ANP infusion are denoted by a P < 0.05, and b p < 0.01. Significant differences between
control values and corresponding values in either of the other two studies are indicated by C P < 0.05, and d p < 0.01.
ological uncertainties it seems fair to assume that ANP sup-
pressed fractional sodium reabsorption in both proximal and
diluting segments. An effect in the proximal tubules may be
hemodynamically mediated, but also a direct one, as suggested
in recent studies (25, 261. By definition, the diluting segment
comprises the entire nephron lying distally from halfway the
medullary thick ascending limb of Henle's loop [21, 27]. We
have tried to further characterize the distal action of ANP by
infusing ANP in combination with amiloride and aldosterone,
which act mainly in the distal nephron. These drugs had no
effect on the initial plasma ANP concentration, and infusion of
ANP consistently increased plasma ANP by about eightfold.
Amiloride, by itself, increased sodium excretion and de-
creased potassium excretion. Presumably, amiloride caused
natriuresis by inhibiting sodium entry through apical sodium
channels throughout the distal nephron, but, due to the limited
dosage, had no proximal effect [13, 28]. This accords with the
clearance data, showing no change in lithium clearance and
distal delivery term, but a marked rise in minimal urine osmo-
lality and the term [(CH20)/(CH2O + Cr1)]. Addition of ANP
increased sodium excretion further, the rise being somewhat
but not significantly less than seen in the control study. This
finding confirms recent results in rabbits [29], and indicates that
ANP can increase natriuresis by a mechanism insensitive to
amiloride.
One option is that ANP decreases proximal tubule sodium
reabsorption by a mechanism not influenced by the presently
used dosage of amiloride. Indeed, ANP increased lithium
clearance also when given on top of amiloride.
Our objective, however, was to find out whether pretreat-
ment with amiloride would interfere with the action of ANP on
the distal nephron. To evaluate this, we have to assume that
ANP infusion caused a comparable decrease in proximal reab-
sorption and, probably, increase in delivery to the distal neph-
ron in the studies with and without amiloride. A different
magnitude of the (further) increase in sodium excretion follow-
ing ANP infusion would then be expected if the extent to which
sodium reabsorption in the distal nephron is suppressed were
different. Thus, if the actions of amiloride and ANP to suppress
sodium reabsorption in the distal nephron are independent, one
would expect a much larger acute increase in sodium excretion
when ANP is given on top of amiloride than when ANP is
infused alone. This was evidently not the case, suggesting that
an effect of ANP on the distal nephron did not come to
Control Amiloride
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A
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Fig. 2. Urine sodium excretion (UNCV, 0)
and potassium excretion (UKV, Will) atbaseline(B) and in the 3rd half hour ofANP infusion
(ANP) during control conditions, and after
pretreatment with amiloride or aldosterone.
Significant differences between baseline and
ANP infusion are denoted by V, P < 0.05,
and , P < 0.01. Significant differences
between control value and corresponding
values of the other two studies are denoted by
I', P < 0.05, and A, P < 0.01.ANP
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expression during amiloride. This idea, based on indirect evi-
dence, is in accordance with more direct data in rabbits, in
which amiloride was shown to block sodium channels in the
IMCD which were probably also ANP sensitive [15]. On the
other hand, amiloride has been shown to increase ANP binding
to adrenal ANP receptors [301, and it remains difficult to say
how, but also where in the distal nephron amiloride and ANP
may interact.
Administration of aldosterone caused a strong retention of
sodium chloride, and a rise in the term [(CH20)/(CH2O + Cc1)],
compatible with increased sodium reabsorption in the collecting
ducts. Potassium excretion remained nonetheless unchanged,
an at first sight unexpected finding also reported by others [31].
Absence of acute kaliuresis probably has multiple causes, one
being the acute fall in plasma potassium [32] as also found in the
present study. In this setting the increase in natriuresis caused
by ANP was not at all blunted. In fact, ANP cancelled much of
the antinatriuretic effect of aldosterone. There are two possible
explanations for this finding. First, ANP infusion may have
elevated sodium delivery to the main sites of aldosterone action
so much that a part of it escaped reabsorption. This must be
weighed against the fact that the aldosterone infusion appeared
able to cause virtually complete reabsorption of distal delivery
prior to ANP. However, the rise in GFR and maximal urine
flow after ANP were exceptionally large in this experiment.
Although the reason for this effect is unclear, it is compatible
with an unusually large increase in distal delivery.
The second option is that ANP and aldosterone act at least
partly in overlapping target segments in the distal nephron,
where ANP now inhibited the antinatriuretic effect of aldoste-
rone. Conceivably, aldosterone not only stimulated sodium
reabsorption along the collecting tubules, but, consequently,
also water back diffusion, even although the studies were
performed during water loading. This could explain the rela-
tively low urine flow during aldosterone, a change also can-
celled by ANP. This possibility of partially overlapping target
nephron segments is in keeping wiht the findings during amilo-
ride.
Since the main site of action of aldosterone is the late distal
tubule and cortical collecting tubule [16—18], an action of ANP
would be suspected here. This is in agreement with recent
findings that ANP increases cGMP accumulation [9] and lowers
sodium reabsorption [10] in isolated perfused rat cortical col-
lecting ducts. The rats in the later study were pretreated with
deoxycorticosterone. Therefore it was held likely that aldoster-
one-sensitive sodium transport and thus also the responsive-
ness to ANP may have been enhanced in these tubules [10].
This is in accordance with our in vivo finding that the natriuretic
effect of ANP is greatly enhanced in humans escaped from the
sodium retaining effect of fludrocortisone [22]. Whether ANP
decreases sodium reabsorption in the aldosterone-sensitive
collecting tubules by inhibition of conductive sodium transport,
as in the case in the IMCD [15], or by another mechanism,
remains to be elucidated.
Alternatively, aldosterone and ANP may interact in the
IMCD. This possibility cannot be ruled out, although the major
sodium retaining effect of aldosterone is prior to this segment.
Two micropuncture studies in rats showed that adrenalectomy
without [33] or with [34] corticosteroid suppletion diminished
sodium reabsorption in this segment. This would indicate a
controlling role of aldosterone also in the physiological range,
and not only in pharmacological amounts as given in the present
study. It has been reported lately that desoxycorticosterone
may increase the reabsorption of sodium chloride in the IMCD
of the rat by diminishing its passive backleak [35] and by
stimulating Na, K-ATPase [36]. Whether this is quantita-
tively important for the antinatriuretic effect of mineralocor-
ticoid is unknown, but it is conceivable that ANP could
neutralize this effect by preventing sodium chloride absorption
through the IMCD apical membrane [15, 35].
As in previous studies [22, 23], the natriuresis induced by
ANP was not associated with a kaliuresis. In fact, in the control
study a fall in potassium excretion was noticed during the
infusion of ANP. A recent study in humans showed the same
fall in potassium excretion during low dose ANP infusion, but a
similar change in a time control study [371. Anyway, it is
remarkable that the natriuresis after ANP was never accompa-
nied by a rise in potassium excretion. Since the role of the
IMCD in potassium secretion is probably limited [18, 38],
absence of a consistent effect of ANP on potassium excretion
would be reconcilable with limitation of its distal effects to the
IMCD. However, this cannot explain why no larger kaliuresis
occurred when ANP was administered during infusion of aldo-
sterone. Again, the low plasma potassium concentration may be
have impaired kaliuresis [32]. Also, since antidiuretic hormone
seems essential as regulating or permissive factor in potassium
secretion in various parts of the distal nephron [39, 40], the
water-loading conditions of our study may have impaired a rise
in potassium excretion.
In summary, the results of these clearance studies in humans
accord with the notion that ANP causes natriuresis by increas-
ing delivery to the distal nephron and by suppressing reabsorp-
tion in a segment of the distal nephron. The latter may very well
concern the IMCD. However, in accordance with recent animal
data, the present results also speak for inhibition of aldoster-
one-sensitive sodium reabsorption, thus for an effect in the
cortical collecting tubules.
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